Key result
Peak sST2, IL-6, osteopontin, and angiopoietin-2 during acute MI correlate with baseline and 12-month LVEF.
Why the study?
To explore the serial 12-month temporal trajectory of eight circulating biomarkers in AMI patients and investigate their association with LVEF during follow-up.
Are temporal trajectories of circulating biomarkers associated with left ventricular ejection fraction in patients following a first acute myocardial infarction?
Cohort (n=155)
Are temporal trajectories of circulating biomarkers associated with left ventricular ejection fraction in patients following a first acute myocardial infarction?
Answers are grounded in this paper and cite their sources.
Peak levels of sST2, IL-6, osteopontin, and angiopoietin-2 during the acute phase of a first MI correlate with LVEF, suggesting their potential as biomarkers for identifying patients at risk of left ventricular dysfunction.
Aims: Our study aimed to explore the temporal trajectory of eight circulating biomarkers, measured serially over 12 months, in a prospective observational cohort of patients with acute myocardial infarction (AMI) and to investigate the association between these biomarkers and left ventricular ejection fraction (LVEF) during follow-up assessments. Methods and results: We enrolled 155 patients admitted for a first AMI requiring percutaneous coronary intervention (PCI). Baseline characteristics, laboratory test results, and cardiac ultrasound examinations were collected at pre-PCI (H0), immediately post-PCI (H24), at discharge (D3), and at 6 months (M6) and 12 months (M12) post-PCI. Blood samples were analysed for established and emerging biomarkers described in left ventricular dysfunction: soluble suppression of tumorigenicity 2 (sST2), interleukin-6 (IL-6), osteopontin, angiopoietin-2, insulin-like growth factor-binding protein 2 (IGFBP-2), growth differentiation factor 15 (GDF-15), hepcidin, and galectin-3. Values at H24, D3, M6, and M12 were compared with value at H0. Three kinetic profiles were identified, with six biomarkers peaking during the acute MI phase. Crude relationships between clinical variables and the peak values (highest observed between H0 and D3) of each biomarker were studied. Peak levels of sST2, IL-6, osteopontin, and angiopoietin-2 demonstrated significant correlations with both baseline and follow-up LVEF values. Conclusion: The assessment of the temporal trajectories of these biomarkers and their associations with LVEF suggests that sST2, IL-6, osteopontin, and angiopoietin-2 hold significant promise as companion biomarkers. These biomarkers may improve the identification of patients at risk for developing impaired LVEF following AMI, thereby enabling more targeted and effective management strategies.
No takes yet. Share an insight, caveat, or question.
Elbaz et al. (2024) conducted a cohort in acute myocardial infarction (AMI) (n=155). Circulating biomarkers (sST2, IL-6, osteopontin, angiopoietin-2, IGFBP-2, GDF-15, hepcidin, galectin-3) was evaluated on Temporal trajectory of eight circulating biomarkers and their association with left ventricular ejection fraction (LVEF). Peak levels of sST2, IL-6, osteopontin, and angiopoietin-2 during the acute MI phase demonstrated significant correlations with both baseline and follow-up LVEF values over 12 months.
Synapse has enriched 10 related papers. Consider them for comparative context: